HC Wainwright & Co. Reiterates Buy on Larimar Therapeutics, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating for Larimar Therapeutics (NASDAQ:LRMR) and maintained a price target of $15.
October 31, 2024 | 9:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating for Larimar Therapeutics, maintaining a $15 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $15 price target by a reputable analyst suggests positive sentiment and confidence in Larimar Therapeutics' future performance. This is likely to have a positive short-term impact on the stock price as investors may view this as a strong endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100